Initial Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion: Shifting Approaches to a Moving Target
- PMID: 37879781
- DOI: 10.1016/j.jacc.2023.08.037
Initial Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion: Shifting Approaches to a Moving Target
Keywords: antithrombotic therapy; atrial fibrillation; left atrial appendage occlusion.
Conflict of interest statement
Funding Support and Author Disclosures Dr Halperin has consulting activities with Bayer HealthCare and the ATLAS Group; and serves on the Steering Committee of the CATALYST trial, sponsored by Abbott. Dr Rothman has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion.J Am Coll Cardiol. 2023 Oct 31;82(18):1765-1773. doi: 10.1016/j.jacc.2023.08.010. Epub 2023 Aug 21. J Am Coll Cardiol. 2023. PMID: 37611779
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
